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The target of rapamycin (TOR) is a highly conserved
Ser/Thr kinase that plays a central role in the control of
cellular growth. TOR has a characteristic multidomain
structure. Only the kinase domain has catalytic func-
tion; the other domains are assumed to mediate interac-
tions with TOR substrates and regulators. Except for the
rapamycin-binding domain, there are no high-resolu-
tion structural data available for TOR. Here, we present
a structural, biophysical, and mutagenesis study of the
extremely conserved COOH-terminal FATC domain. The
importance of this domain for TOR function has been
highlighted in several publications. We show that the
FATC domain, in its oxidized form, exhibits a novel
structural motif consisting of an -helix and a COOH-
terminal disulfide-bonded loop between two completely
conserved cysteine residues. Upon reduction, the flexi-
bility of the loop region increases dramatically. The
structural data, the redox potential of the disulfide
bridge, and the biochemical data of a cysteine to serine
mutant indicate that the intracellular redox potential
can affect the cellular amount of the TOR protein via the
FATC domain. Because the amount of TOR mRNA is not
changed, the redox state of the FATC disulfide bond is
probably influencing the degradation of TOR.
Regulation of cellular growth is a prerequisite for cells, or-
gans, and organisms to achieve a characteristic size. The target
of rapamycin (TOR,1 also known as FRAP, RAFT, RAPT, or
SEPT) is a highly conserved 280-kDa Ser/Thr kinase that has
been shown to play a central role in the control of cell growth in
organisms ranging from yeast to human (1, 2). TOR proteins
consist of several functional domains (see Fig. 1a) (3). The
amino-terminal 1200 residues consist of stretches of HEAT
(huntingtin, elongation factor 3, regulatory subunit A of PP2A,
TOR1) repeats, which typically mediate protein-protein inter-
actions. Recently, it was also suggested that the 550-amino
acid-long FAT (FRAP, ATM, TTRAP) domain that follows the
HEAT repeats is composed of HEAT repeat-like -helical struc-
tures and could also serve as a protein interaction platform (4).
The known interactions of TOR with other proteins have been
reviewed recently (1, 2). The FKBP12-rapamycin binding site is
flanked by the FAT domain and the catalytic kinase domain.
Binding of the FKBP12rapamycin complex to the FKBP12-
rapamycin-binding domain specifically inhibits TOR (5). The
catalytic kinase domain is highly homologous to that of phos-
phatidylinositol 3- and 4-kinases. Thus, TOR and its relatives
have been termed phosphatidylinositol kinase-related kinases.
TOR has been shown to fulfill its functions by directly phos-
phorylating serine and threonine residues of target proteins
and by regulating protein phosphatases (1, 2). The carboxyl-
terminal 33 residues of TOR form the FATC domain. In all
phosphatidylinositol kinase-related kinases, the FATC domain
always occurs in tandem with the FAT domain (6). Previous
studies have shown that the FATC domain is indispensable for
TOR function in vivo and in vitro (7, 8).
Here, we report the solution structure of y1fatc, the FATC
domain of yeast TOR1 (residues 2438–2470), which showed a
new structural motif consisting of an -helix and a disulfide-
bonded loop. Reduction of the disulfide bond resulted in strong
conformational changes and increased flexibility of the loop
region. The structural data, together with the determined in-
termediate range redox potential (0.23 V) and the biochemi-
cal characterization of a Cys to Ser mutant of the full-length
protein, suggest that the cellular stability of TOR toward deg-
radation and possibly its function can be redox-regulated.
EXPERIMENTAL PROCEDURES
Protein Expression—Constructs of the yeast TOR1 FATC (y1fatc)
domain were designed based on sequence conservation. Residues 2438–
2470 were cloned into GEV2 (9) using the BamHI and XhoI sites and
overexpressed in Escherichia coli Rosetta (DE3) (Novagen) in M9 min-
imal medium. About 40% of the IgG-y1fatc fusion protein was in the
soluble fraction obtained after sonication of the cells in 50 mM Tris-HCl,
2 mM EDTA, 2 mM benzamidine, pH 7.5. The remaining 60% of the
protein was extracted from inclusion bodies. Inclusion bodies were
washed with 20 mM Tris-HCl, 1 M urea, pH 7.5, and extracted using 50
mM Tris-HCl, 6 M guanidinium hydrochloride, pH 7.5, with agitation for
1 h at 4 °C. The extract was dialyzed to TST buffer (50 mM Tris buffer,
pH 7.6, 150 mM NaCl, 0.05% Tween 20; equilibration buffer for the
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IgG-Sepharose, see below). IgG-y1fatc fusion protein was extracted
from the cleared lysate and from the dialyzed inclusion body extract
using an IgG-Sepharose 6 fast flow column (Amersham Biosciences) as
described in the manufacturer’s manual. The purified fusion protein
was lyophilized, resuspended in 50 mM Tris, 100 mM NaCl, pH 8, and
desalted using a PD-10 column (Amersham Biosciences). The protein
was eluted with 50 mM Tris-HCl, 100 mM NaCl, pH 8, and, after the
addition of 2 mM CaCl2, digested with Factor Xa (Amersham Bio-
sciences) overnight. After digestion, the fusion partner was removed by
reversed-phase high pressure liquid chromatography in an acetonitrile/
trifluoroacetic acid buffer system, and fractions containing pure y1fatc
were lyophilized. Electrospray mass spectrometry confirmed that y1fatc
had the correct molecular weight. Analytical ultracentrifugation exper-
iments of air oxidized y1fatc in 50 mM Tris, pH 7, showed that y1fatc
was monomeric.
NMR Sample Preparation—Lyophilized 15N- or 15N,13C-labeled
y1fatc was dissolved in 10 mM Tris, pH 8 (in 95% H2O/5% D2O or in
100% D2O), and the pH was adjusted to 6. Reduced samples were
obtained by adding 20 mM Tris(2-carboxylethyl)phosphine-HCl. The
sample for measuring residual dipolar couplings contained about 25
mg/ml PF1 phages (ASLA Biotech). The protein concentration was
always 0.5 mM.
NMR Spectroscopy—NMR spectra were acquired at 298 K on Bruker
DRX600 and 800 spectrometers. The data were processed with
NMRPipe (10) and analyzed using NMRView (11). Assignments for 13C,
15N, and 1H nuclei were based on three-dimensional CBCANH, CBCA-
(CO)NH, HBHA(CBCACO)NH, CCONH-TOCSY (12) and HCCH-
TOCSY, and HNCO spectra. Stereospecific assignments and dihedral
angle information were derived from 3D-HACAHB-COSY, 3D-15N-
ROESY, 3D-HNHA, and 13CO-{13C}-SED- and 15N-{13C}-SED-15N-
1H-HSQC spectra. Distance restraints were obtained from 15N- and
13C-edited NOESY spectra. Information about the backbone dynamics
was derived from the measurement of 15N relaxation experiments in-
cluding T1 (spin-lattice or longitudinal relaxation rate), T2 (spin-spin or
transverse relaxation rate), and (1H)-15N NOE. If not explicitly men-
tioned elsewhere, references for all experiments are given in Ref. 13 and
references therein. 15N-1H residual dipolar couplings were obtained
from the analysis of 15N-1H IPAP-HSQC data (14) acquired on the
sample containing PF1 phages. The maximal 1DN-H was 17.4 Hz.
Structure Calculation—All structure calculations were performed
with XPLOR-NIH (15) using torsion angle molecular dynamics. Dis-
tance restraints were generated in NMRView and classified according
to NOE cross-peak intensities. Upper bounds were 2.8, 3.4 (3.5 for
15N-bound protons), 4.5, and 5.5 Å. The lower bound was always 1.8 Å.
For all NOE restraints, r6 sum averaging was used. Backbone dihedral
angle restraints for  were derived based on 3JHNH and the chemical
shift index (16). Stereospecific assignments were obtained for 14
-methylene proton pairs. Based on 3JHH2/3 coupling constants and
NOE/ROE data, side chain 1 angles were restrained to one of the
staggered conformations (60°, 180°, 60°)  30°. N-H residual dipolar
couplings were included using the SANI statement and an error bound
of 0.2 Hz. The distance between the C atoms of the disulfide bond-
forming cysteines was restrained to be within 4.2–7.0 Å and the dihe-
dral angle around the disulfide bond to be 0°  105°, because the
dihedral angle 3 is always 95° or 95°  10° (17).
Determination of the Redox Potential—The redox potential of y1fatc
was determined by following the protein fluorescence at 350 nm for
different ratios of reduced and oxidized glutathione ([GSH]2/[GSSG])
and analyzing the data as described previously (18). Samples contained
1.1 M y1fatc in 10 mM Tris-HCl, pH 7, 0.1 mM EDTA, 0.1 mM GSSG,
and concentrations of GSH ranging from 10 M to 90 mM. All buffers
were degassed and flushed with argon. The concentration of reduced
glutathione in the buffer was verified with an Ellman assay (19). All
samples were prepared under nitrogen atmosphere. All measurements
were performed at 25 °C (298 K) on an Aminco Bowman series 2
luminescence spectrometer using 1  1-cm quartz cuvettes (right angle
arrangement), an excitation wavelength of 280 nm, and a bandwidth of
4 nm. The bandwidth for detection was 8 nm.
Mutagenesis Studies—Plasmid pJM244 (pTOR2C3S) was con-
structed by PCR amplification of a 1300-bp fragment of the COOH-
terminal region of yeast TOR2 using the primers TOR2D (5-GGT AAA
CAG TTG CCA CAA TTA CAA TTA CAA ACT CTT GAA CTA CAA CAT
GTG TCG CC) and TOR2Rmut (5-GAA CTC GAG TAC AAC TAA GTG
ATT TTC AAT ACA TTA AAA CTA CCA GAA TGG AGA CC) contain-
ing an artificial XhoI restriction site and a single base change (under-
lined) compared with the TOR2 wild-type sequence resulting in the
C2470S mutation. The resulting PCR fragment was digested with SpeI
and XhoI and used to substitute the SpeI-XhoI fragment of plasmid
p206 (20), a yeast centromeric plasmid containing an NH2-terminal
hemagglutinin epitope-tagged TOR2 expressed under the control of its
own promoter. Plasmid pJM232 (pTOR2) was constructed in a similar
way, but with primer TOR2Rnat as TOR2Rmut and with a C instead of
the underlined G, to amplify the wild-type sequence. As a control, the
same centromeric plasmid without the TOR2 sequence (pRS314 
pVector) was used. No additional mutations were introduced in plas-
mids pJM232 and pJM244 as confirmed by sequencing of the SpeI-XhoI
fragment. These plasmids were used to transform the Saccharomyces
cerevisiae strains SH121 and SH221 (21). Yeast strains were grown in
rich medium (yeast extract/peptone/dextrose) or synthetic minimal me-
dium complemented with the appropriate nutrients for plasmid main-
tenance as described previously (22). Paromomycin and rapamycin
were added at the indicated concentration from a concentrated stock to
autoclaved yeast extract/peptone/dextrose with 2% agar prior to gela-
tion. Spot tests of yeast growth were performed as described previously
(23), but plates were incubated at a restrictive temperature (37 °C) for
the thermosensitive allele of TOR2. Immunoprecipitation assays were
performed as described previously (24).
RESULTS
The FATC Structure—The FATC domain of the family of
TOR kinases is highly conserved. Fig. 1b shows an alignment of
the carboxyl-terminal 33 residues of TOR proteins from differ-
ent species. One-third of the residues are completely conserved,
including two cysteines in an i to i 7 spacing. To elucidate the
role of the two cysteines for the structure of the FATC domain,
we first acquired 15N-HSQC spectra of oxidized and reduced
FIG. 1. The domain structure of the tar-
get of rapamycin protein is schematically
depicted in a. FRB, FKBP12-rapamycin
binding. An alignment of the amino acid
sequences of the carboxyl-terminal FATC
domain from TOR proteins from different
organisms is given in b. The numbering in
parentheses corresponds to yeast TOR1
(top line). Note the two conserved cys-
teines connected by a blue line. The se-
quence alignment was generated using
the program ESPript (51).
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y1fatc (Fig. 2). Oxidized y1fatc shows a spectrum characteristic
for a folded protein with well dispersed amide proton nitrogen
cross-peaks for the majority of residues. In the spectrum of the
reduced form, resonances for the carboxyl-terminal 15 residues
(2456–2470) were broadened beyond detection, indicating in-
creased conformational flexibility because of the reduction of
the disulfide bond in this region. To understand the molecular
basis of the differences between the oxidized and the reduced
forms, we have determined the structure of the oxidized form
using standard NMR techniques.
The NMR structure of oxidized y1fatc is shown in Fig. 3, and
structural statistics are given in Table I. The structure consists
of a long, NH2-terminal -helix extending from residue Glu
2444
to the first cysteine, Cys2460 (Fig. 3, a and b), and a COOH-
terminal disulfide-bonded loop from Cys2460 to Cys2467 that
folds the protein chain back onto itself. This chain reversal is
facilitated by the completely conserved glycine at position 2465.
Contacts within the loop are dominated by interactions involv-
ing aromatic side chains (Fig. 3d). Pro2468 makes hydrophobic
as well as C-H interactions with the aromatic rings of
Tyr2463, Trp2466, and Phe2469. The C-H interactions are very
similar to hydrogen bonds and depend on the orientation and
distance of the planes of the involved pyrrolidine and aromatic
rings (25). In y1fatc, many of the pyrrolidine ring protons of
Pro2468 have distances of 4.5 Å to the aromatic carbons of
Trp2466 and Phe2469 and orientations of their ring planes that
are commonly found in such C-H interactions. Additional
hydrophobic contacts involving aromatic and aliphatic side
chains occur between the conserved carboxyl-terminal residues
Phe2469 and Trp2470, Leu2459 and Ile2456, as well as between
Trp2466, Typ2463, and Ile2464. The side chains of Ile2456 and
Leu2459 make further contacts to the methyl groups of Ala2453
and Thr2454, respectively.
From a comparison of the 15N-HSQC (Fig. 2) and circular
dichroism (not shown) spectra of oxidized and reduced y1fatc, it
can be deduced that part of the -helix is also populated in the
reduced form. The 1H-15N cross-peaks for the -helical residues
Glu2444 to Leu2449 do not shift significantly (Fig. 2), indicating
that their chemical and structural environment is maintained.
In contrast, the COOH-terminal region from Ile2456 to Trp2470
becomes clearly more flexible upon reduction of the Cys2460–
Cys2467 disulfide bridge.
The absence of NOEs for the first five NH2-terminal residues
preceding Pro2443 indicates a random coil conformation for this
part of the sequence. Indeed, the 15N relaxation data (Fig. 4)
give evidence of large amplitude backbone motions on the sub-
nanosecond time scale from V2442 onward to the NH2 termi-
nus because of a strong increase in the T2 and T1 relaxation
times and a strong decrease of the (1H)-15N NOEs. T1 values for
the helical and loop part are more uniform, with an average of
0.57  0.08 s, which is close to values expected for an isotro-
pically tumbling molecule of the size of y1fatc (4 kDa) at 25 °C.
In contrast, T2 values (average  0.10  0.04 s) within this
structured part are much smaller (0.4 s) than expected for a
rigid molecule of this size and indicate the presence of consid-
erable line broadening because of chemical exchange on the
microsecond time scale. Note also that the asymmetry of the
helical molecule contributes to a certain extent to the shorten-
ing of the amide 15N T2 values. However, the effect of even very
pronounced asymmetry of the diffusion tensor would be too
small to account for the observed shortening of t2. A more
extended analysis using the program TENSOR (26) and an
isotropic model as a first approximation for the rotational dif-
fusion of y1fatc showed that the chemical exchange contribu-
tions (Rex) increase strongly from the beginning to the end of
the structured part (Fig. 4, bottom panel). The subnanosecond
order parameter S2 also increases from values around 0.3 at
the NH2 terminus to values around 0.8 at the COOH terminus
(Fig. 4, fourth panel). Thus on the subnanosecond time scale,
there are large amplitude motions at the NH2 terminus but
only small amplitude motions at the COOH-terminal end of the
structure. In contrast, micro- to millisecond time scale motions
are stronger in the COOH-terminal half. Therefore, albeit
folded, the helix and loop parts of the FATC structure are
partly flexible, with the time scale of motions becoming longer
toward the COOH terminus. This observation is not surprising
because the FATC domain is stabilized by only a few tertiary
contacts at the COOH-terminal end that are mediated by the
disulfide bridge.
The 13C and 1H resonances of Cys2467 are not visible in the
NMR spectra of y1fatc, and its side chain and the one following
residue Pro2468 show only few and broad NOE contacts. Pre-
sumably, this is because of additional conformational exchange
from disulfide bond crankshaft motions like the ones that have
been characterized in bovine pancreatic trypsin inhibitor (27).
Indeed, in the structure calculations, the left-hand conforma-
tion (17) of the disulfide bond is only slightly more favored (13
of the 20 best structures) than the right-hand conformation.
A second minor set of resonances was observed for the back-
bone amides of residues Phe2469 and Trp2470 (Fig. 2) and for the
Pro2468 C/H nuclei in the 13C-HSQC spectrum. These reso-
nances indicate the presence of a minor cis-form of Pro2468 in
addition to the predominant trans-form. As judged from the
spectral intensities, this cis-form is populated to 15–20%. Very
similar structures for the rest of FATC were obtained when
Pro2468 was constrained to the cis- instead of the trans-confor-
mation (data not shown).
Determination of the Redox Potential—Because both trypto-
phans of y1fatc are in the vicinity of the disulfide bond-forming
cysteines (Fig. 3d), the redox state-dependent fluorescence at
350 nm was used to determine the redox potential (18) of the
Cys2460–Cys2467 disulfide bond of y1fatc. For y1fatc equili-
brated in buffers containing different ratios of oxidized and
reduced glutathione, we detected a two-state transition curve
(Fig. 5a) that corresponds to an equilibrium constant (Keq) of
0.45 M. Using the Nernst equation E0 y1fatc  E0 GSH/GSSG 
(RT/2F) ln Keq, with E0 GSH/GSSG  0.24 V, this results in a
redox potential of 0.23 V for y1fatc. Apparently, this value is
FIG. 2. Two-dimensional 1H-15N HSQC spectrum of oxidized
(black peaks) and reduced (red peaks) y1fatc. The amino acid
sequence of y1fatc is shown at the bottom. Reduction of the intramolec-
ular disulfide bond between Cys2460 and Cys2467 increases the flexibility
of the COOH-terminal half (depicted in black letters in the sequence).
This increased flexibility broadens the resonances of the respective
residues in the reduced form beyond detection.
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very close to the one for glutathione. Other cellular components
(Fig. 5b) are more reducing or more oxidizing than y1fatc, such
as thioredoxin (0.27 V) or cytochrome c (0.22 mV),
respectively.
Mutagenesis Studies—In yeast, two highly homologous TOR
proteins have been identified. TOR1 is only found as part of
TORC1 (complex 1), a multiprotein complex that regulates cell
growth in a rapamycin-sensitive manner. In contrast, TOR2
can be found as part of TORC1 but additionally can participate
in a second protein complex called TORC2. The known func-
tion of the complex TORC2 is to regulate the polarization of the
actin cytoskeleton in a rapamycin-insensitive manner (24). To
study the influence of the FATC disulfide bonds on both com-
plexes, mutagenesis studies were carried out on the TOR2
protein.
In detail, the second of the disulfide bond-forming cysteines
in TOR2 (Cys2470  Cys2467 in TOR1) was changed to serine
(C2470S). To investigate the effect of this TOR2 mutation on
the function of the rapamycin-insensitive complex TORC2, a
plasmid containing the C2470S mutation (pTOR2C3S) was
introduced into the yeast strain SH121 (21) that carries a
thermosensitive allele of TOR2. The pTOR2C3S plasmid was
able to complement the thermosensitive phenotype under re-
strictive temperature conditions (37 °C), where expression of
wild-type TOR2 protein is suppressed (data not shown). Exper-
iments with an isogenic wild-type plasmid (pTOR2) yielded
FIG. 3. NMR structures of y1fatc (with Pro2468 in the major trans-conformation). a, view of the 20 best structures of y1fatc after a least
square alignment of the backbone atoms of residues 2443–2470. The backbone of the -helix is red. The disulfide bond between cysteines 2460 and
2467 is yellow, and the conserved glycine (Gly2465) is orange. Hydrophobic and aromatic side chains are light green in the picture foreground and
dark green in the picture background, and polar or neutral amino acids side chains are light blue. b, ribbon representation of the 20 superposed
structures from a. c, surface representation of the lowest energy structure from a. The surface is colored according to the charge distribution (red,
negative; blue, positive). d, detailed view of the disulfide-bonded loop. All structure pictures were made with the programs MolMol (52) and
POV-Ray.
TABLE I
Statistics for the final 20 of 200 calculated y1fatc
structures (trans-Pro2468)
Experimental restraints
Distance restraints All (assigned  ambiguous)
Total 824 (727  97)
Intraresidue 399 (390  9)
Sequential  medium 389 (315  74)
Long range (i-j 	 4) 36 (22  14)
 angle restraints 26
1 angle restraints 20
1DN-H residual dipolar coupling
restraints
29
Structural statisticsa
r.m.s.b deviations from experimental
restraints
Distance (Å) 0.0161  0.0016
Dihedral angle (°) 0.347  0.177
Residual dipolar coupling (Hz) 0.144  0.024
r.m.s.b deviations from idealized
geometry
Bonds 0.0038  0.0001
Angles 0.496  0.017
Improper 0.365  0.019
Lennard Jones energy (kcal mol1) 95  5
Procheckc statistics (%)
Residues in most favored regions 82.0
Residues in additional allowed
regions
18.0
Residues in generously allowed
regions
0
Residues in disallowed regions 0
Average r.m.s. deviationb to mean
structure (Å)
Residues 6–33 (backbone/heavy) 0.39/0.88
-Helical  7–23 (backbone/heavy) 0.22/0.83
a None of the structures had distance restraints violations 	0.3 Å,
dihedral angle violations	5°, or residual dipolar coupling violations	1
Hz.
b root mean square.
c Ref. 55.
FIG. 4. Backbone dynamics of y1fatc. 15N-T1 (top panel), T2 (sec-
ond panel), and NOE (third panel) values and uncertainties were de-
termined for the oxidized form of this 33-residue protein. Secondary
structure elements and the location of the disulfide bond (SS) are
indicated at the top. A model-free analysis (53, 54) of the 15N relaxation
data was performed using the program TENSOR2 (26). The analysis
was based on an isotropic tumbling model with a rotational correlation
time of 1.9 ns. The Lipari-Szabo model free order parameter S2 and the
contribution of chemical exchange Rex to the observed transverse relax-
ation rate 1/T2 are displayed in the bottom two panels.
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identical results. Thus, the function of complex TORC2 is not
affected by the C2470S mutation.
To investigate the effect of the C2470S mutation on the
function of the rapamycin-sensitive complex TORC1, the
pTOR2C3S plasmid was introduced into the yeast strain
SH221 that is deleted in TOR1 and carries a thermosensitive
allele of TOR2 (21). Switching from the permissive (30 °C) to
the restrictive temperature (37 °C) under normal or stressful
conditions, including oxidative or osmotic stress, did not lead to
a growth defect (data not shown). However, at the restrictive
temperature, the strain carrying plasmid pTOR2C3S was un-
able to grow on medium containing sublethal concentrations of
paromomycin, a protein synthesis inhibitor, or of rapamycin, a
TOR-C1-specific inhibitor (Fig. 6a). In contrast, controls at the
permissive temperature or on the same strain transformed
with the plasmid pTOR2 showed normal growth (Fig. 6a). Thus
the C2470S mutation affects the activity of the rapamycin-
sensitive complex TORC1 in the presence of paromomycin or
rapamycin.
This effect on the activity could be caused by a structural
change within the complex or by a general destabilization of
TOR2 that leads to smaller cellular concentrations. To inves-
tigate this effect further, we performed an immunoprecipita-
tion of TOR2 extracted from yeast cells that were grown iden-
tically at the restrictive temperature (37 °C) and that were
expressing either wild-type or mutated TOR2. The amount of
C2470S TOR2 was 3-fold less than that of wild-type TOR2
(Fig. 6b). Thus, the C2470S mutation reduces the amount of
TOR2 protein, which may explain the paromomycin- and rapa-
mycin-hypersensitive phenotypes described above. To make
sure that the mutation does not simply affect the amount of
TOR2 on the mRNA level, we performed reverse transcription-
PCR experiments (data not shown) using the same strains,
genetic constructs, and growth conditions as for the immuno-
precipitation. These experiments showed that the mutation
does not change either the transcription or, presumably, the
expression level of TOR2 (data not shown). We also performed
immunofluorescence experiments on whole fixed cells to deter-
mine the cellular location of the mutant TOR2, but no changes
in localization compared with wild-type TOR2 were detected
(data not shown).
DISCUSSION
In the present study, we investigated the structure of the
highly conserved yeast TOR1 FATC domain. In its oxidized
form, FATC consists of an -helix and a well structured disul-
fide-bonded loop between two completely conserved cysteines
(Cys2460 and Cys2467). The NH2-terminal half of the helix and
the loop region next to the COOH terminus are rather acidic
(Fig. 3c), whereas the remaining part of the loop is more hy-
drophobic. Therefore, oxidized FATC could bind to a hydropho-
bic surface of complementary shape surrounded by polar resi-
dues. Reduction of the disulfide bond dramatically increases
the flexibility within the COOH-terminal loop region and pre-
sumably the accessibility of several hydrophobic side chains in
this region. Thus the reduction may alter the binding behavior
of FATC to other parts of TOR or other cellular partners.
The redox potential of the Cys2460–Cys2467 disulfide bridge
was determined as 0.23 V. This value is very similar to the
one for glutathione (Fig. 5b). In yeast, a C2470S TOR2 muta-
tion had no significant effect on growth under normal or stress-
ful conditions. However, cells carrying the TOR2 C2470S mu-
tation were hypersensitive to rapamycin and paromomycin.
This observation, together with the fact that TOR2 carrying the
C2470S mutation is less abundant than wild-type TOR2, indi-
cates that the cellular amount of TOR is affected by the redox
state of the FATC domain. Because the level of TOR mRNA is
not changed, the redox state of the FATC disulfide bond is
probably influencing the degradation of TOR.
Commonly, the cytosol is considered to be a reducing envi-
FIG. 5. Determination of the redox potential of y1fatc. The
shown transition curve (a) was obtained by monitoring the fluorescence
at 350 nm of samples containing 1.1 M y1fatc, 0.1 mM oxidized gluta-
thione, and varying concentrations of reduced glutathione (10 M–90
mM). The experimental data were analyzed as described under “Exper-
imental Procedures.” b, scale of the redox potentials of some cellular
components. Redox pairs to the left of y1fatc are more reducing, and
those to the right of y1fatc are more oxidizing.
FIG. 6. The cysteine to serine mutation in yeast TOR2 (C2470S)
induces rapamycin and paromomycin hypersensitivity. These
phenotypes correlate with less TOR2 protein. a, at a restrictive tem-
perature (37 °C), pTOR2C3S is unable to grow in the presence of rapa-
mycin or paromomycin. Precultures of the indicated strains were grown
in selective synthetic minimal media until saturation. Water dilutions
of each strain (1/10, 1/100, and 1/1000) were spotted on yeast extract/
peptone/dextrose medium containing the indicated concentration of
rapamycin or paromomycin, and growth was recorded after 4 days.
Identical results were obtained from at least six independent colonies of
each strain in two separate experiments. b, TOR2C3S protein is less
abundant than TOR2 protein. Cells expressing hemagglutinin-TOR2
(wild type (wt)) and hemagglutinin-TOR2C3S (C3S) were grown (at
37 °C) and harvested, and the protein was extracted in the same way.
The protein concentration was determined by a Bradford assay. Both
cell lysates were subjected to immunoprecipitation with anti-hemagglu-
tinin, and the resulting precipitates were resolved by SDS-PAGE and
Western blotted to detect TOR2. As a control, actin was immunopre-
cipitated in parallel (bottom panel).
Structure of the TOR FATC Domain20562
 at U
niversitaetsbibliothek M
edizin on N
ovem
ber 8, 2017
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
ronment. Very few values of the redox potential in living cells
have been reported. The determination of appropriate values is
hampered because the intracellular redox potential may de-
pend on the location, metabolic state, differentiation, and type
of the cell. The redox potential for the overall intracellular
environment of a mammalian cell line was determined to range
from 0.221 to 0.236 V (28). Using a green fluorescent pro-
tein with an engineered disulfide bond (rxYFP), the redox
potential of the cytosolic glutathione pool of wild-type yeast
cells under normal growth conditions was determined to be
0.289 V but changed to 0.227 V upon mutation of genes
involved in the regulation of the cytosolic glutathione pool (29).
During the life cycle of mammalian cells, the cytosolic redox
potential was found to range between 0.260 and 0.160 V
(30). In proliferating mammalian cells, the redox potential is
0.24 V (28, 31, 32), whereas more oxidizing conditions are
found in differentiating cells (0.2 V) (30) and at the onset of
apoptosis (0.17 to 0.19 V) (31, 32). TOR has also been
found in the nucleus (33). However, to our knowledge, no in-
formation is available on the redox potential within the
nucleus.
Based on the reported cellular redox potentials, it is possible
that TOR exists in both reduced and oxidized forms in the
cellular environment. The ratio of oxidized to reduced TOR
during the cellular life cycle could be altered through the action
of typical cellular redox regulators (glutathione, thioredoxin,
glutathione S-transferase, cytochrome c, reactive oxygen spe-
cies, etc.), in which concentrations depend on metabolic activ-
ities in response to the availability of nutrients, the action of
growth hormones, and the influence of stress (oxidative, UV,
etc.). Furthermore, the local redox potential for the FATC di-
sulfide bond may be modulated within the various TOR
complexes.
Several examples exist of cytosolic and nuclear proteins that
are regulated through the reversible oxidation of a cysteine
side chain. The roles of redox-sensitive proteins involved in
stress responses (34), regulation of cell death (35), and cancer
proliferation (36) have been reviewed recently. Within the TOR
signaling cascade, various redox-dependent proteins or pro-
cesses have been reported. For example, the lipid phosphatase
PTEN, a tumor suppressor, is redox-regulated. Mutations or
loss of PTEN are associated with an increased activation of
mTOR (37, 38). PTEN is inactivated through the reversible
formation of a disulfide bond in its active site (39). Further-
more, it has been suggested that mTOR is involved in the
regulation of hypoxia-inducible factor 1 (40–43) and that
hypoxia can trigger hypophosphorylation of mTOR and some of
its effectors in a hypoxia-inducible factor-independent manner
(41). Obviously low oxygen pressure (hypoxia) should influence
the redox potential within the cell. Additionally, it has been
suggested that the UV response pathway induces the phospho-
rylation of p70 S6 kinase in an mTOR-dependent manner via
the generation of reactive oxygen species (44). Finally, TOR can
associate with the mitochondrial outer membrane (45), which
could make it directly susceptible to (redox) signals from this
organelle.
The effect of mutations within the mTOR FATC domain has
been investigated in two studies (7, 8). Both show that deletion
of the carboxyl-terminal tryptophan as well as small deletions
(three or more residues) of the COOH terminus abolish mTOR
autophosphorylation activity as well as mTOR-dependent
phosphorylation of eukaryotic initiation factor 4E-binding pro-
tein and p70 S6 kinase. Thus, the COOH-terminal deletions
abolished mTOR function. These findings indicate that the
FATC domain interacts with other parts of TOR or other com-
ponents of TOR complexes (24, 46–49) to activate kinase func-
tion. Notably, a C2546A mutation in the FATC domain of
mTOR did not prevent mTOR from autophosphorylating or
activating p70 S6 kinase (7). Nevertheless, from the autoradio-
gram presented, it can be concluded that the degree of p70 S6
kinase activation was lower for mutated than for wild-type
mTOR. In agreement with these data, our C2470S yeast TOR2
mutant is also still active, but its cellular concentration
is lowered.
In conclusion, we have presented the structure of the FATC
domain of yeast TOR1. FATC forms a novel structural motif
consisting of an -helix and a COOH-terminal disulfide-bonded
loop. Upon reduction of this disulfide bond, the flexibility of
FATC increases dramatically. Considering that several redox-
dependent processes can be connected to the TOR signaling
cascade, it seems attractive to propose that the function of TOR
can be redox-regulated via the highly conserved FATC disulfide
bond. Our data indicate that the redox potential of the disulfide
bond is in an intermediate range and that the cellular amount
of TOR is affected by the C2470S mutation. An analogous
redox-regulatory mechanism for the cellular stability of a pro-
tein has been suggested for the phosphatase Cdc25C, which is
involved in the regulation of cell cycle progression (50). Future
biochemical and structural experiments will be required to
shed light on the influence of changes in the cytosolic redox
potential on the FATC domain and its interactions with other
TOR domains or components of TOR complexes.
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